Galderma, the leading pharmaceutical company in dermatology, and Ipsen, an innovation-driven international specialty pharmaceutical group, today announced that Azzalure (botulinum toxin Type A manufactured by Ipsen), a muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in France from the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS).
The details can be read here.
No comments:
Post a Comment